STOCK TITAN
  1. Home
  2. Sec-filings
  3. DYN
  4. [Form 4] Dyne Therapeutics, Inc. Insider Trading Activity

[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock DYN logo
Dyne Therapeutics, Inc.

NASDAQ:DYN

DYN Rankings

#3173 Ranked by Market Cap
N/A Ranked by Dividends

DYN Latest News

Jul 16, 2025
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
Jul 2, 2025
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Jun 30, 2025
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
Jun 30, 2025
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
Jun 30, 2025
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

DYN Latest SEC Filings

Jul 18, 2025
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity
Jul 18, 2025
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity
Jul 1, 2025
[424B5] Dyne Therapeutics, Inc. Prospectus Supplement (Debt Securities)
Jul 1, 2025
[8-K] Dyne Therapeutics, Inc. Reports Material Event

DYN Stock Data

1.25B
132.26M
0.69%
100.83%
10.31%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM